Glucosamine sulfate in the treatment of knee osteoarthritis symptoms - A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator

被引:184
作者
Herrero-Beaumont, Gabriel
Roman Ivorra, Jose Andres
del Carmen Trabado, Maria
Blanco, Francisco Javier
Benito, Pere
Martin-Mola, Emilio
Paulino, Javier
Marenco, Jose Luis
Porto, Armando
Laffon, Armando
Araujo, Domingos
Figueroa, Manuel
Branco, Jaime
机构
[1] Autonomous Univ Madrid, Dept Rheumatol, Fdn Jimenez Diaz Capio, Madrid 28040, Spain
[2] Hosp Dr Peset, Valencia, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] Hosp Univ Juan Canalejo, La Coruna, Spain
[5] Hosp del Mar, Barcelona, Spain
[6] Hosp Univ La Paz, Madrid, Spain
[7] Completo Hosp Ciudad Real, Ciudad Real, Spain
[8] Hosp Nuestra Senora De Valme, Seville, Spain
[9] Hosp Univ Coimbra, Coimbra, Portugal
[10] Hosp De La Princesa, Madrid, Spain
[11] Hosp Conde Bertiandos, Ponte do Lima, Portugal
[12] Hosp Donostia, San Sebastian, Spain
[13] Hosp Egas Moniz, Ctr Hosp Lisboa Occidental, EPE, Lisbon, Portugal
来源
ARTHRITIS AND RHEUMATISM | 2007年 / 56卷 / 02期
关键词
D O I
10.1002/art.22371
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To assess the effects of the prescription formulation of glucosamine sulfate (1,500 mg administered once daily) on the symptoms of knee osteoarthritis (OA) during a 6-month treatment course. Methods. Three hundred eighteen patients were enrolled in this randomized, placebo-controlled, double-blind trial in which acetaminophen, the currently preferred medication for symptomatic treatment of OA, was used as a side comparator. Patients were randomly assigned to receive oral glucosamine sulfate 1,500 mg once daily (n = 106), acetaminophen 3 gm/day ( n = 108), or placebo (n = 104). The primary efficacy outcome measure was the change in the Lequesne index after 6 months. Secondary parameters included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and response according to the Osteoarthritis Research Society International criteria. These outcome measures were assessed using an intent-to-treat analysis. Results. At baseline, the study patients had moderately severe OA symptoms (mean Lequesne index similar to 11 points). Glucosamine sulfate was more effective than placebo in improving the Lequesne score, with a final decrease of 3.1 points, versus 1.9 with placebo (difference between glucosamine sulfate and placebo - 1.2 [95% confidence interval -2.3, -0.8]) (P = 0.032). The 2.7-point decrease with acetaminophen was not significantly different from that with placebo (difference -0.8 [95% confidence interval - 1.9, 0.3]) (P = 0.18). Similar results were observed for the WOMAC. There were more responders to glucosamine sulfate (39.6%) and acetaminophen (33.3%) than to placebo (21.2%) (P = 0.004 and P = 0.047, respectively, versus placebo). Safety was good, and was comparable among groups. Conclusion. The findings of this study indicate that glucosamine sulfate at the oral once-daily dosage of 1,500 mg is more effective than placebo in treating knee OA symptoms. Although acetaminophen also had a higher responder rate compared with placebo, it failed to show significant effects on the algofunctional indexes.
引用
收藏
页码:555 / 567
页数:13
相关论文
共 49 条
[1]   Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society - Results from a workshop [J].
Altman, R ;
Brandt, K ;
Hochberg, M ;
MOskowitz, R ;
Bellamy, N ;
Bloch, DA ;
Buckwalter, J ;
Dougados, M ;
Ehrlich, G ;
Lequesne, M ;
Lohmander, S ;
Murphy, WA ;
RosarioJansen, T ;
Schwartz, B ;
Trippel, S .
OSTEOARTHRITIS AND CARTILAGE, 1996, 4 (04) :217-243
[2]   DEVELOPMENT OF CRITERIA FOR THE CLASSIFICATION AND REPORTING OF OSTEOARTHRITIS - CLASSIFICATION OF OSTEOARTHRITIS OF THE KNEE [J].
ALTMAN, R ;
ASCH, E ;
BLOCH, D ;
BOLE, G ;
BORENSTEIN, D ;
BRANDT, K ;
CHRISTY, W ;
COOKE, TD ;
GREENWALD, R ;
HOCHBERG, M ;
HOWELL, D ;
KAPLAN, D ;
KOOPMAN, W ;
LONGLEY, S ;
MANKIN, H ;
MCSHANE, DJ ;
MEDSGER, T ;
MEENAN, R ;
MIKKELSEN, W ;
MOSKOWITZ, R ;
MURPHY, W ;
ROTHSCHILD, B ;
SEGAL, M ;
SOKOLOFF, L ;
WOLFE, F .
ARTHRITIS AND RHEUMATISM, 1986, 29 (08) :1039-1049
[3]  
Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905
[4]  
BELLAMY N, 1988, J RHEUMATOL, V15, P1833
[5]   Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness [J].
Biggee, BA ;
Blinn, CM ;
McAlindon, TE ;
Nuite, M ;
Silbert, JE .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (02) :222-226
[6]   Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in ostcoarthritic knee pain: meta-analysis of randomised placebo controlled trials [J].
Bjordal, JM ;
Ljunggren, AE ;
Klovning, A ;
Slordal, L .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7478) :1317-1320D
[7]   Fasting serum sulfate levels before and after development of osteoarthritis in participants of the veterans administration normative aging longitudinal study do not differ from levels in participants in whom osteoarthritis did not develop [J].
Blinn, CM ;
Dibbs, ER ;
Hronowski, LJJ ;
Vokonas, PS ;
Silbert, JE .
ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2808-2813
[8]   Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: comment on the article by Brandt and Mazzuca [J].
Bruyere, Olivier ;
Reginster, Jean-Yves ;
Giacovelli, Giampaolo ;
Barbetta, Beatrice ;
Rovati, Lucio C. ;
Pavelka, Karel .
ARTHRITIS AND RHEUMATISM, 2006, 54 (07) :2339-2341
[9]   Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis [J].
Cibere, J ;
Kopec, JA ;
Thorne, A ;
Singer, J ;
Canvin, J ;
Robinson, DB ;
Pope, J ;
Hong, P ;
Grant, E ;
Esdaile, JM .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (05) :738-745
[10]  
Clegg DO, 2005, ARTHRITIS RHEUM-US, V52, pS256